EQUITY RESEARCH MEMO

Imorgon

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)65/100

Imorgon is a healthcare technology company that addresses inefficiencies in radiology reporting, specifically for ultrasound. Its enterprise software platform automates the transfer of DICOM Structured Report (SR) data into reporting systems such as Nuance PowerScribe and seamlessly integrates with Epic EHR. By normalizing data, automating documentation, and providing clinical decision support, Imorgon significantly reduces manual data entry, minimizes errors, and boosts radiologist and sonographer productivity. The platform's focus on structured reporting and workflow automation positions it as a key enabler of operational efficiency in diagnostic imaging. As healthcare systems increasingly prioritize digital transformation and interoperability, Imorgon's solution offers immediate value by streamlining a traditionally labor-intensive process. With a growing emphasis on reducing clinician burnout and improving accuracy, the company is well-placed to capture market share in the radiology IT segment.

Upcoming Catalysts (preview)

  • Q2 2026Integration with a Major PACS Vendor70% success
  • Q3 2026Announcement of Series A Funding60% success
  • Q4 2026Clinical Study Publication Demonstrating Time Savings80% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)